evertex fabrinology limited

TWSE:1470 Stock Report

Market Cap: NT$1.9b

evertex fabrinology Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for evertex fabrinology.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Luxury earnings growth14.0%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Nov 19

Investors Shouldn't Be Too Comfortable With evertex fabrinology's (TWSE:1470) Earnings

Despite posting some strong earnings, the market for evertex fabrinology limited's ( TWSE:1470 ) stock hasn't moved...
Analysis Article • Sep 16

evertex fabrinology limited's (TWSE:1470) Business Is Yet to Catch Up With Its Share Price

evertex fabrinology limited's ( TWSE:1470 ) price-to-earnings (or "P/E") ratio of 32.9x might make it look like a...
Analysis Article • Mar 20

evertex fabrinology's (TWSE:1470) Profits May Not Reveal Underlying Issues

evertex fabrinology limited's ( TWSE:1470 ) stock didn't jump after it announced some healthy earnings. We think that...
Analysis Article • Apr 25

Does evertex fabrinology limited (TPE:1470) Have A Place In Your Dividend Stock Portfolio?

Is evertex fabrinology limited ( TPE:1470 ) a good dividend stock? How can we tell? Dividend paying companies with...
Analysis Article • Mar 26

Be Wary Of evertex fabrinology (TPE:1470) And Its Returns On Capital

When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...
Analysis Article • Mar 05

evertex fabrinology limited's (TPE:1470) Financial Prospects Don't Look Very Positive: Could It Mean A Stock Price Drop In The Future?

evertex fabrinology's (TPE:1470) stock is up by 3.1% over the past month. However, its weak financial performance...
Analysis Article • Feb 12

Does evertex fabrinology's (TPE:1470) Statutory Profit Adequately Reflect Its Underlying Profit?

It might be old fashioned, but we really like to invest in companies that make a profit, each and every year. That...
Analysis Article • Jan 25

Tread With Caution Around evertex fabrinology limited's (TPE:1470) 4.6% Dividend Yield

Dividend paying stocks like evertex fabrinology limited ( TPE:1470 ) tend to be popular with investors, and for good...
Analysis Article • Jan 07

Would Shareholders Who Purchased evertex fabrinology's (TPE:1470) Stock Year Be Happy With The Share price Today?

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While...
Analysis Article • Dec 20

Is evertex fabrinology (TPE:1470) Headed For Trouble?

If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...
Analysis Article • Dec 02

evertex fabrinology limited's (TPE:1470) Financial Prospects Don't Look Very Positive: Could It Mean A Stock Price Drop In The Future?

evertex fabrinology's (TPE:1470) stock is up by 2.0% over the past week. However, its weak financial performance...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as evertex fabrinology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TWSE:1470 - Analysts future estimates and past financials data (TWD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20267817463103N/A
12/31/20258046762101N/A
9/30/2025807596595N/A
6/30/2025824494071N/A
3/31/2025812867599N/A
12/31/20247889785111N/A
9/30/2024702664971N/A
6/30/2024651607497N/A
3/31/202461345110145N/A
12/31/202365549111145N/A
9/30/202363749110141N/A
6/30/202371756183206N/A
3/31/202377741182211N/A
12/31/202284533162189N/A
9/30/202295150201237N/A
6/30/20229685088128N/A
3/31/2022993864780N/A
12/31/202189565-144N/A
9/30/202185867-306N/A
6/30/202177363-3318N/A
3/31/202162625-2436N/A
12/31/2020631351776N/A
9/30/2020647322794N/A
6/30/20206954073132N/A
3/31/20208157271119N/A
12/31/201981876N/A94N/A
9/30/201981479N/A93N/A
6/30/201980277N/A76N/A
3/31/201979262N/A98N/A
12/31/201875449N/A106N/A
9/30/201873547N/A99N/A
6/30/201870436N/A91N/A
3/31/201869340N/A89N/A
12/31/201770142N/A99N/A
9/30/201771142N/A107N/A
6/30/201770339N/A104N/A
3/31/201768240N/A113N/A
12/31/201668647N/A122N/A
9/30/201668750N/A127N/A
6/30/201671364N/A136N/A
3/31/201674562N/A99N/A
12/31/201576261N/A87N/A
9/30/201577063N/A77N/A
6/30/201574754N/A70N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1470's forecast earnings growth is above the savings rate (1.3%).

Earnings vs Market: Insufficient data to determine if 1470's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 1470's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1470's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 1470's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1470's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/24 23:18
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

evertex fabrinology limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.